Lilly Undeterred By UK NICE Funding Blow For Second-Line Use Of Verzenios
UK HTA Body Has Issued A Preliminary Rejection Of Breast Cancer Drug For Routine Use
Verzenios is one of three CDK4/6 inhibitors that are available via the Cancer Drugs Fund for use in previously treated patients with metastatic breast cancer, but it is the first for which health technology assessment body NICE has published a recommendation on routine commissioning.
